Lausanne, Switzerland, July 3, 2023 – AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at ...
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...
DifGen Pharmaceuticals and Aveva Drug Delivery Systems today announced a strategic platform collaboration with Biostax Corp d/b/a Attune Biotech, SGP Holdings, and Callan JMB to lead U.S.-based ...
The purpose of this undergraduate minor is to leverage Drexel’s unique strengths and leadership in this area to advance the education of the next generation of leaders in immune engineering. Students ...
AFFiRiS is a clinical-stage biotechnology company located in Vienna, Austria, with a vision of using the immune system to identify and target human proteins central to the development and progression ...
The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer program Target ALS Foundation grant supports collaboration between AC Immune and ...
LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results